New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
07:19 EDTXXII, FNJN, CLIR, APGI, HIPP, NEO, TNXP, LOCMLD Micro to hold a conference
LD Micro 4th Invitational Conference to be held in Los Angeles on June 4.
Sign up for a free trial to see the rest of the stories you've been missing.
October 2, 2015
08:57 EDTXXII22nd Century says milestone study using Spectrum cigarettes published by NEJM
Subscribe for More Information
September 25, 2015
08:34 EDTFNJNFinjan says PTAB denies dual petitions for IPR
Finjan Holdings announced that the Patent Trial and Appeal Board, or PTAB, for the United States Patent & Trademark Office denied dual petitions for inter partes review (IPR) by Sophos for Finjan patents; 8,677,494 "Malicious Mobile Code Runtime Monitoring System and Methods," with docket number IPR2015-01022 and 7,613,926 "Method and System for Protecting a Computer and a Network from Hostile Downloadables," with docket number IPR2015-00907. The patent lawsuit filed in March of 2014 against Sophos will continue with these and six other Finjan patents, as originally filed. The other six Finjan patents in the litigation include; 6,154,844, 6,804,780, 7,613,918, 7,757,289, 8,141,154, and 8,566,850.
September 24, 2015
08:02 EDTCLIRClearSign Combustion promotes Robert Ruiz to COO
Subscribe for More Information
September 23, 2015
08:38 EDTFNJNFinjan wins 23rd patent from USPTO for malicious mobile code protection
Subscribe for More Information
07:03 EDTNEONeoGenomics launches new cervical assay for abnormal pap tests
NeoGenomics announced an expansion of its comprehensive Fluorescence In Situ Hybridization, or FISH, testing menu to include a new NeoSITE Cervical assay to provide additional diagnostic information on abnormal Pap smears. The NeoSITE Cervical assay evaluates abnormalities in five chromosomal loci. This testing can be used for diagnosis, for prediction of prognosis, and for monitoring precancerous and cancerous cervical lesions.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use